Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

Related Citations for PubMed (Select 23563900)

1.

Predictive factors in patients with advanced and metastatic squamous cell carcinoma of the head and neck: a study based on SWOG protocol S0420.

Mehta S, Moon J, Hashmi M, Leblanc M, Huang CH, Rinehart E, Wolf GT, Urba SG, Banerjee SK, Williamson S.

Oncol Rep. 2013 Jun;29(6):2095-100. doi: 10.3892/or.2013.2374. Epub 2013 Apr 2.

2.

Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420.

Williamson SK, Moon J, Huang CH, Guaglianone PP, LeBlanc M, Wolf GT, Urba SG.

J Clin Oncol. 2010 Jul 10;28(20):3330-5. doi: 10.1200/JCO.2009.25.6834. Epub 2010 May 24.

3.

A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck.

Abdul Razak AR, Soulières D, Laurie SA, Hotte SJ, Singh S, Winquist E, Chia S, Le Tourneau C, Nguyen-Tan PF, Chen EX, Chan KK, Wang T, Giri N, Mormont C, Quinn S, Siu LL.

Ann Oncol. 2013 Mar;24(3):761-9. doi: 10.1093/annonc/mds503. Epub 2012 Oct 28.

4.

Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.

Elser C, Siu LL, Winquist E, Agulnik M, Pond GR, Chin SF, Francis P, Cheiken R, Elting J, McNabola A, Wilkie D, Petrenciuc O, Chen EX.

J Clin Oncol. 2007 Aug 20;25(24):3766-73.

5.

A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer.

Argiris A, Cohen E, Karrison T, Esparaz B, Mauer A, Ansari R, Wong S, Lu Y, Pins M, Dancey J, Vokes E.

Cancer Biol Ther. 2006 Jul;5(7):766-70. Epub 2006 Jul 2.

6.

A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer.

Fury MG, Sherman E, Lisa D, Agarwal N, Algazy K, Brockstein B, Langer C, Lim D, Mehra R, Rajan SK, Korte S, Lipson B, Yunus F, Tanvetyanon T, Smith-Marrone S, Ng K, Xiao H, Haque S, Pfister DG.

J Natl Compr Canc Netw. 2012 Nov 1;10(11):1391-8.

PMID:
23138167
7.

Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.

Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, Vokes EE.

J Clin Oncol. 2003 May 15;21(10):1980-7.

PMID:
12743152
8.

Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.

Schöffski P, Catimel G, Planting AS, Droz JP, Verweij J, Schrijvers D, Gras L, Schrijvers A, Wanders J, Hanauske AR.

Ann Oncol. 1999 Jan;10(1):119-22.

9.

Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck.

Vermorken JB, Licitra L, Stöhlmacher-Williams J, Dietz A, Lopez-Picazo JM, Hamid O, Hossain AM, Chang SC, Gauler TC.

Eur J Cancer. 2013 Sep;49(13):2877-83. doi: 10.1016/j.ejca.2013.05.002. Epub 2013 May 30.

PMID:
23726971
10.

[The effect of the microenvironment of head and neck cancers on tumor progression].

Lukits J.

Magy Onkol. 2009 Mar;53(1):51-9. doi: 10.1556/MOnkol.53.2009.1.8. Hungarian.

11.

Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma.

Tsao AS, Liu S, Fujimoto J, Wistuba II, Lee JJ, Marom EM, Charnsangavej C, Fossella FV, Tran HT, Blumenschein GR, Papadimitrakopoulou V, Kies MS, Hong WK, Stewart DJ.

J Thorac Oncol. 2011 Dec;6(12):2104-11. doi: 10.1097/JTO.0b013e31822e7256.

PMID:
21892101
12.

Elevated expression of T-lymphoma invasion and metastasis inducing factor 1 in squamous-cell carcinoma of the head and neck and its clinical significance.

Wang S, Li S, Yang X, Yang S, Liu S, Liu B, Liu J.

Eur J Cancer. 2014 Jan;50(2):379-87. doi: 10.1016/j.ejca.2013.10.003. Epub 2013 Nov 1.

PMID:
24189000
13.
14.

Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase II randomized study.

Caponigro F, Rosati G, De Rosa P, Avallone A, De Rosa V, De Lucia L, Comella P, Comella G.

Oncology. 2002;63(3):232-8.

PMID:
12381902
15.

Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

Cohen EE, Kane MA, List MA, Brockstein BE, Mehrotra B, Huo D, Mauer AM, Pierce C, Dekker A, Vokes EE.

Clin Cancer Res. 2005 Dec 1;11(23):8418-24.

16.
17.

Autocrine and paracrine chemokine receptor 7 activation in head and neck cancer: implications for therapy.

Wang J, Seethala RR, Zhang Q, Gooding W, van Waes C, Hasegawa H, Ferris RL.

J Natl Cancer Inst. 2008 Apr 2;100(7):502-12. doi: 10.1093/jnci/djn059. Epub 2008 Mar 25.

18.

S-1 monotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck after progression on platinum-based chemotherapy.

Yokota T, Onozawa Y, Boku N, Hamauchi S, Tsushima T, Taniguchi H, Todaka A, Machida N, Yamazaki K, Fukutomi A, Yasui H.

Jpn J Clin Oncol. 2011 Dec;41(12):1351-7. doi: 10.1093/jjco/hyr147. Epub 2011 Oct 5.

19.

Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma.

Shin DM, Khuri FR, Glisson BS, Ginsberg L, Papadimitrakopoulou VM, Clayman G, Lee JJ, Ang KK, Lippman SM, Hong WK.

Cancer. 2001 Apr 1;91(7):1316-23.

PMID:
11283932
20.

CCND1 as a predictive biomarker of neoadjuvant chemotherapy in patients with locally advanced head and neck squamous cell carcinoma.

Feng Z, Guo W, Zhang C, Xu Q, Zhang P, Sun J, Zhu H, Wang Z, Li J, Wang L, Wang B, Ren G, Ji T, Tu W, Yang X, Qiu W, Mao L, Zhang Z, Chen W.

PLoS One. 2011;6(10):e26399. doi: 10.1371/journal.pone.0026399. Epub 2011 Oct 31.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk